Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 482.86 KB
Add to list
  1. Search results
  2. Raltitrexed in mesothelioma

Raltitrexed in mesothelioma

Veerle Surmont (UGent) and Jan Van Meerbeeck (UGent)
(2011) EXPERT REVIEW OF ANTICANCER THERAPY. 11(10). p.1481-1490
Author
Organization
Abstract
Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase II trials exploring the activity of raltitrexed either as a single agent or in combination with a platinum agent, a Phase III randomized study demonstrated that the combination of raltitrexed and cisplatin improves overall survival in malignant pleural mesothelioma (MPM) and is superior compared with cisplatin alone, without harmful effect on health-related quality of life. Moreover, the cost-effectiveness analysis found raltitrexed plus cisplatin to be cost effective compared with cisplatin and compared with active supportive care. Based on these results, raltitrexed is registered for the treatment of MPM in several European countries. MPM is hard to treat and has a poor prognosis. New treatment options, such as a combination of cisplatin and raltitrexed, which improve patient outcomes with no detrimental effect on quality of life, are a welcome addition to our therapeutic portfolio.
Keywords
ZD1694, TS inhibitor, Tomudex (R), raltitrexed, quality of life, mesothelioma, MALIGNANT-PLEURAL-MESOTHELIOMA, THYMIDYLATE SYNTHASE INHIBITOR, PHASE-II TRIAL, NATIONAL-CANCER-INSTITUTE, CELL LUNG-CANCER, QUINAZOLINE ANTIFOLATE, ICI D1694, COLORECTAL-CANCER, CHEMOTHERAPY, CISPLATIN

Downloads

  • Download
    (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 482.86 KB

Citation

Please use this url to cite or link to this publication:

MLA
Surmont, Veerle, and Jan Van Meerbeeck. “Raltitrexed in Mesothelioma.” EXPERT REVIEW OF ANTICANCER THERAPY, vol. 11, no. 10, 2011, pp. 1481–90, doi:10.1586/ERA.11.136.
APA
Surmont, V., & Van Meerbeeck, J. (2011). Raltitrexed in mesothelioma. EXPERT REVIEW OF ANTICANCER THERAPY, 11(10), 1481–1490. https://doi.org/10.1586/ERA.11.136
Chicago author-date
Surmont, Veerle, and Jan Van Meerbeeck. 2011. “Raltitrexed in Mesothelioma.” EXPERT REVIEW OF ANTICANCER THERAPY 11 (10): 1481–90. https://doi.org/10.1586/ERA.11.136.
Chicago author-date (all authors)
Surmont, Veerle, and Jan Van Meerbeeck. 2011. “Raltitrexed in Mesothelioma.” EXPERT REVIEW OF ANTICANCER THERAPY 11 (10): 1481–1490. doi:10.1586/ERA.11.136.
Vancouver
1.
Surmont V, Van Meerbeeck J. Raltitrexed in mesothelioma. EXPERT REVIEW OF ANTICANCER THERAPY. 2011;11(10):1481–90.
IEEE
[1]
V. Surmont and J. Van Meerbeeck, “Raltitrexed in mesothelioma,” EXPERT REVIEW OF ANTICANCER THERAPY, vol. 11, no. 10, pp. 1481–1490, 2011.
@article{2044515,
  abstract     = {{Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase II trials exploring the activity of raltitrexed either as a single agent or in combination with a platinum agent, a Phase III randomized study demonstrated that the combination of raltitrexed and cisplatin improves overall survival in malignant pleural mesothelioma (MPM) and is superior compared with cisplatin alone, without harmful effect on health-related quality of life. Moreover, the cost-effectiveness analysis found raltitrexed plus cisplatin to be cost effective compared with cisplatin and compared with active supportive care. Based on these results, raltitrexed is registered for the treatment of MPM in several European countries. MPM is hard to treat and has a poor prognosis. New treatment options, such as a combination of cisplatin and raltitrexed, which improve patient outcomes with no detrimental effect on quality of life, are a welcome addition to our therapeutic portfolio.}},
  author       = {{Surmont, Veerle and Van Meerbeeck, Jan}},
  issn         = {{1473-7140}},
  journal      = {{EXPERT REVIEW OF ANTICANCER THERAPY}},
  keywords     = {{ZD1694,TS inhibitor,Tomudex (R),raltitrexed,quality of life,mesothelioma,MALIGNANT-PLEURAL-MESOTHELIOMA,THYMIDYLATE SYNTHASE INHIBITOR,PHASE-II TRIAL,NATIONAL-CANCER-INSTITUTE,CELL LUNG-CANCER,QUINAZOLINE ANTIFOLATE,ICI D1694,COLORECTAL-CANCER,CHEMOTHERAPY,CISPLATIN}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{1481--1490}},
  title        = {{Raltitrexed in mesothelioma}},
  url          = {{http://doi.org/10.1586/ERA.11.136}},
  volume       = {{11}},
  year         = {{2011}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: